Cepton Secures Industry’s Largest ADAS Lidar Series Production Win with Leading Detroit-Based Global Automotive OEM
13.7.2021 16:00:00 EEST | Business Wire | Press release
Lidar solutions provider Cepton Technologies, Inc. (“Cepton”) announced that it has secured an ADAS lidar series production award at a leading, Detroit-based global automotive OEM (“Detroit-based OEM”), which is the industry’s largest award to-date [1]. This represents a landmark milestone both for the lidar industry as well as for Silicon Valley-based Cepton, which celebrates its five-year anniversary this month.
The Detroit-based OEM is expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars. This marks the potential for an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.
Cepton secured this path-breaking, series production win in partnership with Koito Manufacturing Co., Ltd. (“Koito”), a leading automotive lighting Tier 1 supplier that is both a Cepton partner and investor. With this partnership, Cepton has provided a non-exclusive license to Koito to manufacture a version of Cepton’s MMT ®-based Vista®-X90 automotive grade lidar, using key components and technologies from Cepton. Substantial progress has been made in the Vista®-X90 product development over the past 18 months since the series production award.
The multiple OEM vehicle models already awarded as part of this series production program makes this win the largest in the industry to-date. The deployment of Cepton lidars in those vehicle models, as well as anticipated models to be added in the coming years at the Detroit-based OEM, is expected to significantly exceed that in any of the other publicly announced lidar series production programs. This is a testament to Cepton’s patented MMT® lidars, which utilize a rotation-free, mirrorless and frictionless technology that balances outstanding performance, high reliability and low cost, which are the three key factors integral to delivering mass-market ADAS lidar. Cepton’s MMT® lidars also feature a superior combination of compact size and low power consumption, which maximizes flexibility for vehicle integration, enabling various placement options such as in the fascia, in headlamps, on the roof and behind windshields. Cepton’s Vista®-X90 lidar consequently enables seamless and innovative vehicle-lidar integration.
“We are thrilled to work with an automotive OEM that is not just considered one of the global leaders in the industry but also a recognized pioneer and leader in ADAS and autonomous driving,” said Cepton CEO and co-founder, Dr. Jun Pei. “We are honored to have been chosen to help fulfill their long-term vision for vehicle safety and autonomy. We are also gratified to partner with Koito and leverage their manufacturing and quality leadership in this pathbreaking series production program, which I believe will set the standard for future ADAS lidar adoption.”
Dr. Pei added, “We founded Cepton in 2016 with an emphasis on ADAS and centered our lidar innovation around the goal of making lidar an essential automotive safety sensor in everyday passenger cars. We are now focused on delivering a safer and more enjoyable driving experience to consumers within the next few years.”
About Cepton
Cepton is one of the world’s leading providers of state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements herein are “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect Cepton’s current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject to various risks and uncertainties, including (i) the success of our strategic relationships, including with our Tier 1 partners and OEM customers, none of which are exclusive; (ii) fluctuations in sales of Cepton’s major customers; (iii) current trends in the automotive markets. Cepton does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
[1] Largest known series production award by number of vehicle models awarded and based on publicly available information
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005461/en/
Contact information
Cepton Media Relations: Faithy Li - media@cepton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 09:00:00 EEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 06:49:00 EEST | Press release
Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 20:16:00 EEST | Press release
Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s global C-130H fleet from 10 aircraft to 20 and gives its Canadian division the scale to build
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
